F

Fresenius Medical Care AG & Co KGaA
NYSE:FMS

Watchlist Manager
Fresenius Medical Care AG & Co KGaA
NYSE:FMS
Watchlist
Price: 22.62 USD -0.66% Market Closed
Market Cap: $13.3B

P/B

0.8
Current
5%
Cheaper
vs 3-y average of 0.9

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.8
=
Market Cap
$11.2B
/
Total Equity
€13.3B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.8
=
Market Cap
$11.2B
/
Total Equity
€13.3B

Valuation Scenarios

Fresenius Medical Care AG & Co KGaA is trading below its 3-year average

If P/B returns to its 3-Year Average (0.9), the stock would be worth $23.74 (5% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+107%
Average Upside
56%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 0.8 $22.62
0%
3-Year Average 0.9 $23.74
+5%
5-Year Average 0.9 $25.28
+12%
Industry Average 1.6 $45.38
+101%
Country Average 1.7 $46.83
+107%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Lower than 94% of companies in Germany
Percentile
6th
Based on 2 701 companies
6th percentile
0.5
Low
0 — 1.1
Typical Range
1.1 — 2.8
High
2.8 —
Distribution Statistics
Germany
Min 0
30th Percentile 1.1
Median 1.7
70th Percentile 2.8
Max 125.7

Fresenius Medical Care AG & Co KGaA
Glance View

Fresenius Medical Care AG & Co KGaA, articulating a saga of innovation and resilience, stands at the global forefront of dialysis care. Born out of a convergence of medical expertise and humanitarian ambition, the company caters to individuals battling chronic kidney disease. It operates through an intricate network of dialysis clinics and manufacturing facilities spread across continents. These clinics are the lifeline for many, transforming what is essentially a life-threatening condition into a manageable routine. The process is remarkable: patients are connected to dialysis machines, many of which are crafted by Fresenius itself. These machines emulate the essential functions of kidneys by filtering and purifying blood, a process pivotal for sustaining life in those with kidney failure. The dual avenues of Fresenius Medical Care's revenue generation create a unique synergy driving the company's success. One arm of its business involves providing essential dialysis treatments through its expansive clinic network, offering healthcare services directly to patients worldwide. The other arm engages in the production and sale of dialysis products, encompassing everything from dialysis machines to a wide range of associated medical supplies. Hospitals and other healthcare providers across the globe depend on these products, further broadening Fresenius's impact and revenue streams. This symbiotic integration of services and products not only reinforces its market leadership but also aligns the company's growth with advancements in patient outcomes and healthcare technology.

FMS Intrinsic Value
53.78 USD
Undervaluation 58%
Intrinsic Value
Price $22.62
F
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett